Deppe G, Malviya V K, Zbella E
Wien Klin Wochenschr. 1984 Oct 26;96(20):747-56.
A review of single agents and combination chemotherapy, with or without progestins, in the treatment of recurrent or metastatic endometrial carcinoma is presented. Doxorubicin, hexamethylmelamine, and cis-diamminedichloroplatinum are considered to be the most active drugs for the treatment of this disease. To date, combination chemotherapy has not shown any advantage over single agent therapy. The role of progestins in the treatment depends upon the presence of progesterone receptor binding sites. Better designed, randomized multi-institutional trials, using these drug combinations or new agents, singly or in combination, are necessary to identify optimal chemotherapy for patients with advanced or recurrent endometrial cancer.
本文综述了单用化疗药物及联合化疗（无论是否联合孕激素）治疗复发性或转移性子宫内膜癌的情况。阿霉素、六甲蜜胺和顺二氯二氨铂被认为是治疗该疾病最有效的药物。迄今为止，联合化疗并未显示出比单药治疗更具优势。孕激素在治疗中的作用取决于孕激素受体结合位点的存在情况。有必要开展设计更合理的多机构随机试验，单独或联合使用这些药物组合或新药物，以确定晚期或复发性子宫内膜癌患者的最佳化疗方案。
